Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Ferring Pharmaceuticals110 enrolled

Overview

This multicenter, randomized, open-label exploratory study will be performed in approximately 200 polycystic ovary syndrome (PCOS) but otherwise healthy females undergoing in vitro fertilization (IVF). Each study center will follow its standard practice for in vitro fertilization (IVF) within the study parameters as noted in this protocol. The study centers will use marketed products purchased from Schraft's Pharmacy for all phases of the study (down-regulation, stimulation, ovulation induction, and luteal support). Subjects will be randomly assigned to highly purified menotropin (Menopur®) or follitropin beta (Follistim Pen®) for stimulation and progesterone vaginal insert (Endometrin®) or progesterone in oil for luteal support. Subjects will return to the study center for regular scheduled clinic visits as required per in vitro fertilization (IVF) protocol at the site and at specified times during the cycle (Stimulation Day 6, Day of human chorionic gonadotropin (hCG), and first serum pregnancy test) for estradiol (E2), progesterone (P4) and human chorionic gonadotropin (hCG) labs. All subjects will be required to complete a final study visit at completion of luteal support or negative serum pregnancy test following embryo transfer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

110

Conditions

Polycystic Ovarian Syndrome Infertility

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Pre-menopausal females between the ages of 18 and 42 years 2. Diagnosed with polycystic ovary syndrome (PCOS), using criteria adopted as the 2003 Rotterdam PCOS Consensus (2 out of 3, excluding other etiologies \[congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome\]) * Oligo- or anovulation * Clinical and/or biochemical signs of hyperandrogenism * Polycystic ovaries 3. Body mass index (BMI) of 18-39 4. Early follicular phase (Day 3) follicle stimulating hormone (FSH) \< 15 IU/L and estradiol (E2) within normal limits 5. Documented history of infertility (e.g., unable to conceive for at least one year, or for 6 months for women \> 38 years of age, or bilateral tubal occlusion or absence, or male factor but excluding severe male factor requiring invasive or surgical sperm retrieval. Donor sperm may be used.) 6. Transvaginal ultrasound at screening consistent with findings adequate for assisted reproductive technology (ART) with respect to uterus and adnexa 7. Signed informed consent Exclusion Criteria: 1. Gestational or surrogate carrier, donor oocyte 2. Presence of any clinically relevant systemic disease (e.g., uncontrolled thyroid or adrenal dysfunction, an organic intracranial lesion such as a pituitary tumor, insulin-dependent diabetes mellitus, uterine cancer) 3. Surgical or medical condition which, in the judgment of the Investigator or Sponsor, may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used 4. Two or more previous failed in vitro fertilization (IVF) cycles or in vitro fertilization (IVF)/assisted reproductive technology (ART) failure due to a poor response to gonadotropins, defined as development of 2 mature follicles 5. History of recurrent pregnancy loss, defined as more than two clinical losses 6. Presence of abnormal uterine bleeding of undetermined origin 7. Current or recent substance abuse, including alcohol or smoking \> 10 cigarettes per day 8. Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests 9. Participation in any experimental drug study within 30 days prior to Screening 10. Severe male factor requiring invasive or surgical sperm retrieval (e.g., microsurgical epididymal sperm aspiration \[MESA\], testicular sperm extraction \[TESE\]) 11. Prior hypersensitivity to any of the protocol drugs

Outcomes

Primary Outcomes

Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3

A count of participants whose discontinuation was clearly documented on the study completion/termination form as cycle cancellation for risk of ovarian hyperstimulation syndrome (OHSS).

Time frame: weeks 1-3

Secondary Outcomes

Number of Follicles Observed at Day 15

The mean number of follicles observed in both ovaries at the last transvaginal ultrasound in the stimulation phase.

Time frame: approximately day 15

Number of Oocytes Retrieved at Day 18

The mean number of oocytes retrieved approximately 36 hours after hCG (Novarel®) administration and fertilized (by insemination or intra cytoplasmic sperm injection (ICSI)) according to site-specific procedures.

Time frame: approximately day 18

Percentage of Oocytes Fertilized of the Total Number of Oocytes Retrieved

The fertilization rate for each participant was the percentage of the number of oocytes inseminated of the total number of oocytes retrieved.

Time frame: approximately day 19

Number of Embryos Transferred at Three Stages of Development Before Implantation

The number of embryos, morulas and blastocysts transferred to the study participant on either day 3 or day 5 following fertilization. Embryos represent the earliest development stage and contain 2-8 cells. Morulas, the next stage, continued cellular cleavage results in a 16-30 cell solid sphere. Morula further develop into blastocyst, which contains 70-100 cells in a hollow spherical shape.

Time frame: approximately day 24

Number of Embryos Frozen

The number of embryos that were not transferred but instead were frozen for future use.

Time frame: approximately day 24

Percentage of Participants With Biochemical Pregnancy at Approximately Day 38

Biochemical pregnancy is a positive β-hCG pregnancy test 12-14 days post embryo transfer.

Time frame: approximately day 38 (Day 14 post embryo transfer)

Percentage of Participants With Clinical Pregnancy at Week 7

Clinical pregnancy is the confirmation of the presence of intrauterine gestational sacs on pregnancy ultrasound examination.

Time frame: approximately Day 52

Percentage of Participants With Ongoing Pregnancy at Week 9

Clinical pregnancy is the confirmation of the presence of intrauterine gestational sacs on pregnancy ultrasound examination.

Time frame: approximately Day 65

Estradiol Levels at Day 6

Estradiol monitoring during fertility therapy assesses follicular growth and is useful in monitoring the treatment. Blood tests sent to a central laboratory to obtain estradiol levels.

Time frame: Day 6

Human Chorionic Gonadotropin (hCG) Levels at Day 6

Blood tests were sent to a central laboratory to obtain hCG levels.

Time frame: Day 6

Progesterone Levels at Human Chorionic Gonadotropin (hCG) Administration

Blood tests were sent to a central laboratory to obtain progesterone levels.

Time frame: approximately day 16

Number of Live Births Resulting From the In Vitro Fertilization Process

Number of live births resulting from the IVF process

Time frame: Approximately 10 months

Participants With Treatment Emergent Adverse Events

Number of participants with adverse events (AEs) that started after first treatment. Severity used a three point scale: mild=awareness of signs/symptoms, but no disruption of usual activity moderate=event sufficient to affect usual activity (disturbing) severe=event causes inability to work or perform usual activities (unacceptable) Relatedness to study treatment used a four point scale: unrelated, unlikely, possible, probable. Seriousness refers to death, hospitalization, a life-threatening experience, persistent or significant disability/incapacity, or congenital anomaly.

Time frame: Week 1 to week12